ARWR

Equity

Arrowhead Pharmaceuticals, Inc.

Health Care · Biotechnology

$63.27

+63.27 (+0.00%)

Open

N/A

Day Range

$62.47 - $64.14

52W Range

$9.57 - $76.76

Volume

2M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns

Simply Wall St. 12 hours ago

Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines

GlobeNewswire 2 days ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Business Wire 5 days ago

Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited

Insider Monkey Feb 18, 2026

ARWR: Strong Start for REDEMPLO Commercialization…

Zacks Small Cap Research Feb 11, 2026

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
ABT Abbott Laboratories $116.35 N/A 2.06% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
ACB Aurora Cannabis Inc. $3.84 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%
A Agilent Technologies, Inc. $121.38 N/A 0.82% +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

arrowheadpharma.com →

🐂 Bull Score

Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.

F 0/100

Very Risky

Bull Score

- No consecutive dividend growth 0/25
- Negative profit margin 0/15
Limited data — score may change as more metrics become available

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

35

Unsafe

Based on 4 fundamental factors

- Negative profit margin

Analysis Tools

Sign in for analysis tools

Share